Connor, Clark & Lunn Investment Management (CC&L)
ANIK icon

Connor, Clark & Lunn Investment Management (CC&L)’s Anika Therapeutics ANIK Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,736
Closed -$330K – 1632
2026
Q1 		$330K Sell
22,736
-37,145
-62% -$431K ﹤0.01% 1400
2025
Q4 		$575K Buy
59,881
+13,943
+30% +$134K ﹤0.01% 1271
2025
Q3 		$432K Buy
45,938
+2,944
+7% +$28.1K ﹤0.01% 1288
2025
Q2 		$455K Buy
42,994
+8,573
+25% +$108K ﹤0.01% 1282
2025
Q1 		$517K Sell
34,421
-6,984
-17% -$116K ﹤0.01% 1136
2024
Q4 		$682K Sell
41,405
-16,201
-28% -$320K ﹤0.01% 1060
2024
Q3 		$1.42M Sell
57,606
-1,212
-2% -$31.4K 0.01% 766
2024
Q2 		$1.49M Sell
58,818
-1,266
-2% -$32.8K 0.01% 742
2024
Q1 		$1.53M Buy
60,084
+7,442
+14% +$180K 0.01% 750
2023
Q4 		$1.19M Buy
52,642
+512
+1% +$10.6K 0.01% 811
2023
Q3 		$971K Buy
52,130
+5,505
+12% +$114K 0.01% 831
2023
Q2 		$1.21M Buy
46,625
+30,627
+191% +$820K 0.01% 743
2023
Q1 		$459K Buy
+15,998
New +$476K ﹤0.01% 910
2016
Q1 		– Sell
-7,500
Closed -$286K – 827
2015
Q4 		$286K Buy
+7,500
New +$287K ﹤0.01% 638
2015
Q1 		– Sell
-8,800
Closed -$359K – 566
2014
Q4 		$359K Sell
8,800
-17,900
-67% -$700K ﹤0.01% 437
2014
Q3 		$979K Sell
26,700
-3,800
-12% -$164K 0.01% 309
2014
Q2 		$1.5M Sell
30,500
-14,600
-32% -$649K 0.01% 276
2014
Q1 		$2.05M Buy
45,100
+15,900
+54% +$591K 0.02% 272
2013
Q4 		$1.18M Buy
+29,200
New +$901K 0.01% 339

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ANIK Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Anika Therapeutics (ANIK) in Q2 2026, closing a stake of 22,736 shares — an estimated $330K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ANIK in Q4 2013 and held it in 19 quarters. The position peaked at $2.05M in Q1 2014. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Anika Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 22,736 Anika Therapeutics shares in Q2 2026, an estimated $330K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Anika Therapeutics in Q4 2013 and held it in 19 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Anika Therapeutics position peaked at $2.05M in Q1 2014.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.